<List><item><source>MED</source><extId>30103412</extId><pmcid>PMC6115976</pmcid><annotations><annotation><prefix>nical trials (e.g., </prefix><exact>NCT00404326</exact><postfix>, NCT00395655, NCT00</postfix><tags><tag><name>NCT00404326</name><uri>http://identifiers.org/clinicaltrials/NCT00404326</uri></tag></tags><id>http://europepmc.org/articles/PMC6115976#europepmc-56a1638400361f9abb3550f9049b07f4</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>als (e.g., NCT00404326, </prefix><exact>NCT00395655</exact><postfix>, NCT00404508). </postfix><tags><tag><name>NCT00395655</name><uri>http://identifiers.org/clinicaltrials/NCT00395655</uri></tag></tags><id>http://europepmc.org/articles/PMC6115976#europepmc-33ef5f3807fffff74e40b2df13748c8a</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>als (e.g., NCT00404326, NCT00395655, </prefix><exact>NCT00404508</exact><postfix>). </postfix><tags><tag><name>NCT00404508</name><uri>http://identifiers.org/clinicaltrials/NCT00404508</uri></tag></tags><id>http://europepmc.org/articles/PMC6115976#europepmc-83bef0f5b2892f7d125407cab2792e8d</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> pancreatic cancer (</prefix><exact>NCT00094445</exact><postfix>) and non-metastatic</postfix><tags><tag><name>NCT00094445</name><uri>http://identifiers.org/clinicaltrials/NCT00094445</uri></tag></tags><id>http://europepmc.org/articles/PMC6115976#europepmc-55df58222b362f5c9d1b44989882f45a</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>) and non-metastatic bladder cancer (</prefix><exact>NCT00666562</exact><postfix>). </postfix><tags><tag><name>NCT00666562</name><uri>http://identifiers.org/clinicaltrials/NCT00666562</uri></tag></tags><id>http://europepmc.org/articles/PMC6115976#europepmc-21980823867bbbe2c5bb79ed9eefef5b</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ry B-cell lymphoma (</prefix><exact>NCT03010982</exact><postfix>) and is also in pha</postfix><tags><tag><name>NCT03010982</name><uri>http://identifiers.org/clinicaltrials/NCT03010982</uri></tag></tags><id>http://europepmc.org/articles/PMC6115976#europepmc-e375032116cfd4d850feb74b60994189</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>y synovial sarcoma (</prefix><exact>NCT02601950</exact><postfix>) (clinical trial id</postfix><tags><tag><name>NCT02601950</name><uri>http://identifiers.org/clinicaltrials/NCT02601950</uri></tag></tags><id>http://europepmc.org/articles/PMC6115976#europepmc-c11b2d90417a7f6906cb8bfef56cad18</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ia (EudraCT Number: </prefix><exact>2013-002447-29</exact><postfix>), whereas GSK287955</postfix><tags><tag><name>2013-002447-29</name><uri>http://identifiers.org/euclinicaltrials/2013-002447-29</uri></tag></tags><id>http://europepmc.org/articles/PMC6115976#europepmc-bdcbd24e1a6358806bd0ae905e7db217</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>EUDRACT</subType></annotation></annotations></item></List>